Intracellular CTLA4 and regulatory T Cells in patients with laryngeal squamous cell carcinoma

Immunological Investigations

Volumn 42, Issue 2, 2013, Pages 81-90

  Erfani, Nasrollah ^a   Khademi, Behzad ^b   Haghshenas, Mohammad Reza ^a   Mojtahedi, Zahra ^a   Khademi, Bijan ^b   Ghaderi, Abbas ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CTLA 4; FoxP3; Head and Neck cancer; Laryngeal squamous cell carcinoma (SCC); Regulatory T cells; Tumor immunology

Indexed keywords

CD19 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LARYNX SQUAMOUS CELL CARCINOMA; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; TUMOR VOLUME;

AGED; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84872474621     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2012.708376     Document Type: Article

References (29)

1. Agarwala, S. S., Ribas, A. (2010). Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J. Immunother. 33(6): 557-569.
2. Alhamarneh, O., Agada, F., et al. (2011). Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck 33(3): 415-423.
3. Ascierto, P. A., Marincola, F. M., et al. (2011). Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med. 9(1):196.
4. Calabro, L., Danielli, R., et al. (2010). Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin. Oncol. 37(5):460-467.
5. Chen, B., Lu, L. M., et al. (2010). [Expression and clinical significance of CCR6, CCR7 and CD4(+)CD25(+) Foxp3(+) regulatory T cells in laryngeal squamous cell carcinoma and neck lymphatic metastasis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 45(9):759-764.
6. Curiel, T. J., Coukos, G., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (9):942-949. (Pubitemid 39273735)
7. Egen, J. G., Allison, J. P. (2002). Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16(1):23-35. (Pubitemid 34143214)
8. Erfani, N., Mehrabadi, S. M., et al. (2012). Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77(2):306-311.
9. Erfani, N., Razmkhah, M., et al. (2010). Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Cancer Invest. 28(8):828-832.
10. Ghaderi, A. (2011). CTLA4 Gene variants in autoimmunity and cancer: A comparative review. Iran. J. Immunol. 8(3):127-149.
11. Hoover, S. K., Frank, J. L., et al. (1991). Activation and in vitro expansion of tumorreactive T lymphocytes from lymph nodes draining human primary breast cancers. J. Surg. Oncol. 46(2): 117-124.
12. Huang, C., Fu, Z. X. (2011). Localization of IL-17+Foxp3+ T cells in esophageal cancer. Immunol. Invest. 40(4):400-412.
13. Ichihara, F., Kono, K., et al. (2003). Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9(12):4404-4408. (Pubitemid 37248397)
14. Jonuleit, H., Schmitt, E., et al. (2001). Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193(11):1285-1294. (Pubitemid 32524778)
15. Kono, K., Kawaida, H., et al. (2006). CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55(9):1064-1071. (Pubitemid 43800721)
16. Kosmaczewska, A., Bocko, D., et al. (2011). Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T Cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol. Oncol. Res.18(2): 479-489.
17. Lindsten, T., Lee, K. P., et al. (1993). Characterization of CTLA-4 structure and expression on human T cells. J. Immunol. 151(7):3489-3499. (Pubitemid 23282661)
18. Linsley, P. S., Bradshaw, J., et al. (1996). Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4(6):535-543. (Pubitemid 26233307)
19. Liyanage, U. K., Moore, T. T., et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169(5):2756-2761. (Pubitemid 34921025)
20. Llinas, L., Lazaro, A., et al. (2011). Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. Immunol. Lett. 134 (2):113-121.
21. Motta, M., Rassenti, L., et al. (2005). Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19(10):1788-1793. (Pubitemid 41486157)
22. Ormandy, L. A., Hillemann, T., et al. (2005). Increased populations of regulatory T cells in peripheralbloodof patientswithhepatocellular carcinoma.CancerRes.65(6):2457-2464. (Pubitemid 40490158)
23. Sawan, S., Burt, D. J., et al. (2011). Circulating regulatory T cells in endometrial cancer: A role for age and menopausal status. Immunol. Invest. 40(1):62-75.
24. Schaefer, C., Kim, G. G., et al. (2005). Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 92 (5):913-920. (Pubitemid 40462639)
25. Strauss, L., Bergmann, C., et al. (2007). The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13(21):6301-6311. (Pubitemid 350075018)
26. Viguier, M., Lemaitre, F., et al. (2004). Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173(2):1444-1453. (Pubitemid 38924326)
27. Wang, X. B., Kakoulidou, M., et al. (2002). Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 130(1):224-232. (Pubitemid 35240010)
28. Woo, E. Y., Chu, C. S., et al. (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61(12):4766-4772. (Pubitemid 32691889)
29. Xerri, L., Devilard, E., et al. (1997). In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J. Pathol. 183(2):182-187. (Pubitemid 27436022)